Selective JAK1 Inhibitor Ivarmacitinib Shows Meaningful Benefit in Active Ankylosing Spondylitis Trial
Ankylosing spondylitis, commonly known as AS and now often classified under the broader term radiographic axial spondyloarthritis, is a chronic inflammatory arthritis that primarily targets the spine and sacroiliac joints, the joints connecting the base of the spine to the pelvis. The persistent inflammation it causes can, over time, lead to the gradual fusion of vertebrae, resulting in severe pain, stiffness, and significant loss of spinal mobility. The disease typically begins in young adulthood, and because its early symptoms can be vague and shared by other conditions, diagnosis is often delayed by years.
Existing treatments include nonsteroidal anti-inflammatory drugs, biologic therapies targeting tumor necrosis factor, and interleukin-17 inhibitors, all of which have helped many people with AS achieve better disease control. However, a substantial portion of patients do not respond adequately to available options, or cannot tolerate them, which makes continued development of new therapies an important priority.
A study published in Arthritis and Rheumatology and highlighted by the Spondylitis Association of America in July 2025 evaluated ivarmacitinib, a selective oral inhibitor of JAK1, one of the intracellular enzymes that relays inflammatory signals in immune cells. JAK inhibitors as a class are already used in rheumatoid arthritis and other inflammatory conditions, but ivarmacitinib is distinguished by its high selectivity for JAK1 specifically, which researchers believe may allow it to block inflammatory pathways relevant to AS while limiting effects on other JAK family members and their associated functions.
In the clinical trial, 48.7 percent of patients with active AS who received ivarmacitinib 4 mg achieved at least a 20 percent improvement in symptoms by week 12, a response threshold known as ASAS20. In the placebo group, 29 percent reached this threshold. Higher-level response rates also favored the treatment arm. The drug was generally well tolerated across the study, and the researchers described the findings as promising enough to support continued development. For people with ankylosing spondylitis who have not achieved adequate relief from current biologic treatments, the prospect of a selective oral JAK1 inhibitor is an encouraging development, pending the larger confirmatory trials and regulatory review that would be needed before it could reach clinical use.